Charles River Laboratories International, Inc. (CRL)
Automate Your Wheel Strategy on CRL
With Tiblio's Option Bot, you can configure your own wheel strategy including CRL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRL
- Rev/Share 81.9674
- Book/Share 69.169
- PB 2.4766
- Debt/Equity 0.8308
- CurrentRatio 1.3604
- ROIC 0.0687
- MktCap 8315869364.0
- FreeCF/Share 11.7702
- PFCF 14.375
- PE -119.9669
- Debt/Assets 0.3685
- DivYield 0
- ROE -0.0201
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRL | Robert W. Baird | Neutral | Outperform | -- | $199 | Nov. 6, 2025 |
| Upgrade | CRL | William Blair | Market Perform | Outperform | -- | -- | Oct. 6, 2025 |
| Upgrade | CRL | Barclays | Equal Weight | Overweight | -- | $195 | Oct. 2, 2025 |
| Upgrade | CRL | Jefferies | Hold | Buy | -- | $195 | Sept. 9, 2025 |
| Upgrade | CRL | Citigroup | Neutral | Buy | -- | $200 | July 9, 2025 |
| Upgrade | CRL | Redburn Atlantic | Neutral | Buy | -- | $182 | May 23, 2025 |
| Upgrade | CRL | TD Cowen | Hold | Buy | -- | $179 | May 14, 2025 |
| Upgrade | CRL | Evercore ISI | In-line | Outperform | -- | $170 | May 8, 2025 |
| Downgrade | CRL | Goldman | Buy | Neutral | $190 | $170 | March 21, 2025 |
| Upgrade | CRL | Citigroup | Sell | Neutral | $155 | $175 | March 4, 2025 |
News
Charles River Laboratories International, Inc. (CRL) Q3 2025 Earnings Call Transcript
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. ( CRL ) Q3 2025 Earnings Call November 5, 2025 9:00 AM EST Company Participants Todd Spencer - Corporate Vice President of Investor Relations James Foster - Chairman, President & CEO Michael Knell - Interim CFO, Corporate Senior VP & Chief Accounting Officer Conference Call Participants Patrick Donnelly - Citigroup Inc., Research Division David Windley - Jefferies LLC, Research Division Elizabeth Anderson - Evercore ISI Institutional Equities, Research Division Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Justin Bowers - Deutsche Bank AG, Research Division Casey Woodring - JPMorgan Chase & Co, …
Read More
Charles River Beat Expectations But Why Is The Stock Falling?
Published: November 05, 2025 by: Benzinga
Sentiment: Negative
Charles River Laboratories International Inc. (NYSE:CRL) stock is trading lower on Wednesday after the company released third-quarter 2025 earnings. It also provided an update on the company's strategic review.
Read More
Charles River: Mixed Q3 As Strategic Review Disappoints
Published: November 05, 2025 by: Seeking Alpha
Sentiment: Negative
Charles River Laboratories remains a "Hold" as strategic review yields minimal change and a sale is unlikely. CRL faces slow organic growth, shrinking backlog, and ongoing pressure in its core DSA segment, with limited near-term demand recovery. Cost-cutting, selective divestitures, and a new $1 billion buyback authorization offer some support, but growth headwinds persist.
Read More
Charles River (CRL) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Charles River (CRL) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
CRL's Q3 Earnings Top Estimates, Revenues Decline Y/Y, Stock Falls
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Charles River beats Q3 profit and revenue forecasts but posts year-over-year declines and narrows its 2025 outlook.
Read More
Charles River Laboratories (CRL) Q3 Earnings and Revenues Surpass Estimates
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River Laboratories (CRL) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.59 per share a year ago.
Read More
Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Published: October 24, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders. If you currently own Charles River stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click he.
Read More
Here's How Charles River Stock Is Placed Ahead of Q3 Earnings
Published: October 24, 2025 by: Zacks Investment Research
Sentiment: Neutral
CRL heads into Q3 earnings with steady RMS growth but faces DSA headwinds from tight biotech budgets.
Read More
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Published: October 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
3 Medical Service Industry Stocks Poised to Counter Workforce Issues
Published: October 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Here are three resilient medical services stocks, Labcorp, Charles River Laboratories and Teladoc, that are poised to outperform amid staffing shortages and digital healthcare growth.
Read More
CRL Stock Rises Following New Strategic Oncology Collaborations
Published: September 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River shares rise after new collaborations with PICI and CHLA, boosting its oncology and cell therapy pipeline momentum.
Read More
Charles River Laboratories International, Inc. (CRL) Presents At Baird 2025 Global Healthcare Conference (Transcript)
Published: September 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (NYSE:CRL ) Baird 2025 Global Healthcare Conference September 10, 2025 9:40 AM EDT Company Participants James Foster - Chairman, President & CEO Conference Call Participants Eric Coldwell - Robert W. Baird & Co. Incorporated, Research Division Presentation Eric Coldwell Senior Research Analyst Good morning, everyone.
Read More
Charles River Laboratories International, Inc. (CRL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Published: September 09, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (NYSE:CRL ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 10:00 AM EDT Company Participants James Foster - Chairman, President & CEO Conference Call Participants Kallum Titchmarsh - Morgan Stanley, Research Division Presentation Kallum Titchmarsh Equity Analyst Okay. Great. I think we can get started.
Read More
Is it the Right Time to Add CRL Stock to Your Portfolio Now?
Published: September 04, 2025 by: Zacks Investment Research
Sentiment: Neutral
Charles River's DSA growth, acquisitions and collaborations support momentum, but forex and macro headwinds weigh on its outlook.
Read More
Charles River Stock May Benefit From Joining EASYGEN Consortium
Published: September 01, 2025 by: Zacks Investment Research
Sentiment: Positive
CRL joins EASYGEN to speed CAR-T therapy delivery, which may boost patient access and investor sentiment.
Read More
Interpreting Charles River (CRL) International Revenue Trends
Published: August 11, 2025 by: Zacks Investment Research
Sentiment: Negative
Review Charles River's (CRL) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Read More
Charles River Laboratories International, Inc. (CRL) Q2 2025 Earnings Call Transcript
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (NYSE:CRL ) Q2 2025 Earnings Conference Call August 6, 2025 9:00 AM ET Company Participants Flavia H. Pease - Corporate Executive VP & CFO James C.
Read More
Charles River: Margin Fears Outweigh Solid Q2
Published: August 06, 2025 by: Seeking Alpha
Sentiment: Negative
Charles River Laboratories posted a strong Q2 beat, but results were boosted by one-time items and cost cuts that may not be sustainable. Ongoing risks include regulatory pressure to phase out animal testing and weak organic revenue growth, especially in the Discovery and Safety Assessment segment. Management raised full-year guidance, but H2 faces margin and revenue headwinds; Q3 EPS is expected to decline sequentially.
Read More
Charles River (CRL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Charles River (CRL) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Read More
Charles River Laboratories (CRL) Q2 Earnings and Revenues Surpass Estimates
Published: August 06, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River Laboratories (CRL) came out with quarterly earnings of $3.12 per share, beating the Zacks Consensus Estimate of $2.5 per share. This compares to earnings of $2.8 per share a year ago.
Read More
Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: Should You Buy?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Charles River Q2 Earnings Preview: What's in Store for the Stock?
Published: July 30, 2025 by: Zacks Investment Research
Sentiment: Positive
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
Read More
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Published: July 22, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Is it Prudent to Retain Charles River Stock in Your Portfolio Now?
Published: July 16, 2025 by: Zacks Investment Research
Sentiment: Negative
CRL sees momentum in drug discovery and safety services, but macro pressures and currency headwinds threaten growth.
Read More
Why Is Charles River (CRL) Down 0.1% Since Last Earnings Report?
Published: June 06, 2025 by: Zacks Investment Research
Sentiment: Negative
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Read More
Charles River Stock May Gain From Extended CHDI Research Deal on HD
Published: June 02, 2025 by: Zacks Investment Research
Sentiment: Positive
CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.
Read More
Charles River Laboratories to Present at William Blair and Jefferies Conferences
Published: June 02, 2025 by: Business Wire
Sentiment: Neutral
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories to Present at William Blair and Jefferies Conferences.
Read More
Should You Continue to Hold Charles River Stock in Your Portfolio?
Published: May 20, 2025 by: Zacks Investment Research
Sentiment: Positive
CRL stays on investors' radars due to the strength of partnerships and segmental prospects.
Read More
S&P 500 Gains & Losses Today: Stocks Gain in Volatile Session as Markets React to Fed Meeting, Trump Trade Comments
Published: May 07, 2025 by: Investopedia
Sentiment: Neutral
The S&P 500 broke a two-session losing streak, rising Wednesday as stocks gained ground in volatile trading following the Federal Reserve's decision to keep interest rates unchanged.
Read More
About Charles River Laboratories International, Inc. (CRL)
- IPO Date 2000-06-23
- Website https://www.criver.com
- Industry Medical - Diagnostics & Research
- CEO James C. Foster
- Employees 18700